Endo International PLC (NASDAQ:ENDP)‘s stock had its “market perform” rating reissued by equities researchers at BMO Capital Markets in a note issued to investors on Friday. They presently have a $11.00 price objective on the stock, down from their prior price objective of $15.00. BMO Capital Markets’ price objective would indicate a potential upside of 45.70% from the company’s previous close.
A number of other equities research analysts have also recently issued reports on the company. Morgan Stanley cut their target price on Endo International PLC from $12.00 to $8.00 and set an “equal weight” rating on the stock in a research note on Thursday. Cowen and Company reiterated a “hold” rating and issued a $16.00 target price on shares of Endo International PLC in a research note on Thursday. Citigroup Inc. restated a “neutral” rating and set a $11.00 price objective (down from $14.00) on shares of Endo International PLC in a research note on Thursday. Mizuho restated a “buy” rating and set a $19.00 price objective on shares of Endo International PLC in a research note on Thursday. Finally, Royal Bank Of Canada set a $9.00 price objective on shares of Endo International PLC and gave the company a “hold” rating in a research note on Thursday. Three equities research analysts have rated the stock with a sell rating, sixteen have assigned a hold rating and five have issued a buy rating to the stock. The company has a consensus rating of “Hold” and an average target price of $14.86.
Shares of Endo International PLC (NASDAQ ENDP) traded down 1.3298% on Friday, hitting $7.4496. 5,126,161 shares of the company were exchanged. The firm’s market cap is $1.66 billion. The company has a 50-day moving average price of $11.04 and a 200 day moving average price of $11.59. Endo International PLC has a 52-week low of $7.43 and a 52-week high of $24.93.
Endo International PLC (NASDAQ:ENDP) last posted its earnings results on Tuesday, August 8th. The company reported $0.93 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.74 by $0.19. The company had revenue of $875.73 million for the quarter, compared to analysts’ expectations of $832.66 million. Endo International PLC had a positive return on equity of 37.58% and a negative net margin of 126.93%. The firm’s quarterly revenue was down 4.9% compared to the same quarter last year. During the same period last year, the business posted $0.86 earnings per share. Analysts predict that Endo International PLC will post $3.51 EPS for the current fiscal year.
ILLEGAL ACTIVITY WARNING: This report was reported by Ticker Report and is the sole property of of Ticker Report. If you are viewing this report on another site, it was stolen and republished in violation of US & international copyright and trademark legislation. The correct version of this report can be accessed at https://www.tickerreport.com/banking-finance/2801008/endo-international-plc-nasdaqendp-earns-hold-rating-from-bmo-capital-markets.html.
In related news, COO Terrance J. Coughlin purchased 20,000 shares of the company’s stock in a transaction that occurred on Thursday, August 10th. The shares were purchased at an average price of $7.70 per share, with a total value of $154,000.00. Following the purchase, the chief operating officer now owns 181,369 shares of the company’s stock, valued at approximately $1,396,541.30. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 0.50% of the company’s stock.
A number of institutional investors have recently added to or reduced their stakes in ENDP. First Quadrant L P CA acquired a new position in Endo International PLC during the first quarter valued at $24,556,000. OppenheimerFunds Inc. boosted its position in Endo International PLC by 182.9% in the first quarter. OppenheimerFunds Inc. now owns 2,873,153 shares of the company’s stock valued at $32,065,000 after buying an additional 1,857,678 shares during the period. Bank of New York Mellon Corp boosted its position in Endo International PLC by 38.7% in the first quarter. Bank of New York Mellon Corp now owns 2,271,111 shares of the company’s stock valued at $25,345,000 after buying an additional 633,904 shares during the period. Diamond Hill Capital Management Inc. acquired a new position in Endo International PLC during the second quarter valued at $5,454,000. Finally, Ameriprise Financial Inc. boosted its position in Endo International PLC by 685.0% in the first quarter. Ameriprise Financial Inc. now owns 554,138 shares of the company’s stock valued at $6,185,000 after buying an additional 483,545 shares during the period. 93.00% of the stock is currently owned by institutional investors.
About Endo International PLC
Endo International PLC, formerly Endo Health Solutions Inc is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services. The Company has a portfolio of branded pharmaceuticals that includes brands, such as Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel.
Receive News & Ratings for Endo International PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International PLC and related companies with MarketBeat.com's FREE daily email newsletter.